A study to evaluate the safety, tolerability and distribution of TB0010 in head and neck squamous cell carcinoma
This is an early-stage study, meaning it's one of the first times this new medicine, called TB0010, is being given to people. The main goal is to check how safe it is and if patients can cope with any side effects. Doctors also want to understand how the medicine travels and works inside the body. This study is specifically for adults who have a type of head and neck cancer that has a particular marker called EGFR-Positive. It’s an important first step in understanding if TB0010 could be a helpful future treatment option.
A colpo d'occhio
Di cosa tratta questo studio?
This study is about a new medicine called TB0010, which is being tested for the first time in people. It's designed for a type of cancer that starts in the head and neck area. Specifically, it's for head and neck squamous cell carcinoma, and only for those cancers that show a certain characteristic called "EGFR-Positive". This means the cancer cells have a particular protein on their surface that the new medicine might target.
The main aim of this first study is to find out if TB0010 is safe to give to people and to see what side effects people might experience. It's very common for new medicines to go through these early safety checks before they can be tested further. Researchers will also be looking at how the medicine is absorbed, distributed, and removed from the body.
Understanding these basic things about a new medicine is a crucial first step. If TB0010 is found to be safe and well-tolerated, it could then move on to bigger studies to see how well it actually treats the cancer. This kind of research helps doctors find new ways to fight cancer in the future.
Punti chiave
- This is an early study testing a new medicine called TB0010.
- It's for a specific type of head and neck cancer (EGFR-Positive).
- The main goal is to check how safe the medicine is.
- Participants will receive the new medicine and have regular check-ups.
- Your involvement could help doctors find future treatments for cancer.
Chi può essere idoneo?
This study is for adults diagnosed with a specific type of head and neck cancer. Your doctors will need to check if your cancer has a particular feature called "EGFR-Positive." This is an important detail that makes your cancer suitable for this specific treatment.
To join, you must be at least 18 years old. There is no upper age limit, meaning older adults can also be considered. Both men and women are welcome to take part if they meet all the other requirements.
Your cancer care team will review all your health information and conduct some tests to confirm if you are a good fit for this study. They will be able to tell you exactly if your medical situation matches the study's needs.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- Hai 18 anni o più?
- Have you been diagnosed with head and neck squamous cell carcinoma?
- Has your doctor confirmed your cancer is 'EGFR-Positive'?
- Are you able to attend regular clinic appointments and tests?
Cosa comporta la partecipazione?
Taking part in this study would involve regular visits to the clinic so doctors can give you the new medicine (TB0010) and check your health. You would also have different tests, such as blood tests, scans, and possibly other medical examinations, to see how the medicine is affecting your body and the cancer. These tests help the doctors understand if the medicine is safe and how it's working.
There will be a set schedule for these visits and tests throughout the study. After you stop taking the medicine, there will usually be some follow-up appointments to monitor your health. The total time you spend in the study will depend on the study plan, but your doctor can give you a clear timeline.
Rischi e benefici potenziali
Luoghi (1)
- —Non verificatoFinlandia
Domande comuni
What does 'EGFR-Positive' mean?
It means your cancer cells have a specific protein called EGFR on their surface. This study medicine is designed to target this particular protein.
Riceverò sicuramente il nuovo medicinale?
Yes, if you join this study, everyone will receive the new medicine called TB0010, as it's testing its safety for the first time in people.
Che tipo di test avrò?
You'll likely have blood tests, scans (like CT or MRI), and regular check-ups to monitor your health and see how your body is reacting to the medicine.
Per quanto tempo sarò nello studio?
The exact duration can vary, but your study team will explain the full schedule of treatments and follow-up appointments when you discuss joining.
E se cambio idea sulla partecipazione?
You are free to leave the study at any point, for any reason. Your decision will not affect your future medical care.
Come saperne di più
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Interessato a partecipare?
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.